Product Description
Mechanisms of Action: p53 Inducer
Novel Mechanism: Yes
Modality: Small Molecule
Route of Administration: Intravenous
FDA Designation: *
Approval Status: Not Approved
Approved Countries: None
Approved Indications: None
Known Adverse Events: None
Company: Sun Yat-sen University
Company Location:
Company CEO:
Additional Commercial Interests: None
Clinical Description
Countries in Clinic:
Active Clinical Trial Count:
Recent & Upcoming Milestones
Highest Development Phases
Phase 4: Breast Cancer|Gastrointestinal Cancer
Phase 3: Esophageal Cancer|Osteosarcoma|Hepatocellular Carcinoma|Colorectal Cancer|Liver Cancer
Phase 2: Colorectal Cancer|Squamous Cell Carcinoma|Breast Cancer|Head and Neck Cancer|Nasopharyngeal Cancer|Small Cell Lung Cancer|Triple Negative Breast Cancer|Gastrointestinal Cancer|Osteosarcoma
Phase 1: Kidney Cancer|Intestinal Diseases|Small Cell Lung Cancer|Gastrointestinal Cancer|Breast Diseases|Kidney Diseases|Nasopharyngeal Cancer|Liver Cancer|Bone Cancer|Head and Neck Cancer|Bone Marrow Diseases|Breast Cancer|Nasopharyngeal Diseases|Non-Small-Cell Lung Cancer
Trial ID |
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
Latest Trial Update Date |
Data Updated |
|---|---|---|---|---|---|---|---|---|
ChiCTR2500114072 |
ChiCTR2500114072 | N/A |
Not yet recruiting |
Triple Negative Breast Cancer |
2031-09-30 |
|||
ChiCTR2400094426 |
ChiCTR2400094426 | N/A |
Recruiting |
Triple Negative Breast Cancer |
2027-10-31 |
|||
NCT07093931 |
MA-BC-III-HER2+-001 | P4 |
Not yet recruiting |
Breast Cancer |
2027-08-01 |
2025-07-31 |
Primary Endpoints|Treatments |
|
NCT06688175 |
2022-KY062 | P2 |
Enrolling by invitation |
Nasopharyngeal Cancer |
2026-12-31 |
2024-11-15 |
Primary Endpoints|Treatments |
|
NCT05766605 |
2022-KY-298-01 | P3 |
Recruiting |
Hepatocellular Carcinoma |
2026-01-01 |
2024-11-27 |
Primary Endpoints|Treatments |
|
NCT05701436 |
2022-KY-277-01 | P3 |
Recruiting |
Liver Cancer |
2026-01-01 |
2024-11-27 |
Primary Endpoints |
|
NCT06169410 |
RNPLS-01 | P4 |
Recruiting |
Gastrointestinal Cancer |
2025-12-31 |
2024-01-24 |
Patient Enrollment|Primary Endpoints|Treatments|Trial Status |
|
ChiCTR1800020175 |
ChiCTR1800020175 | N/A |
Not yet recruiting |
Breast Cancer |
2025-09-01 |
|||
NCT06714383 |
SMA-OS-001 | P2 |
Recruiting |
Osteosarcoma |
2025-07-01 |
2024-12-04 |
Primary Endpoints|Treatments |
|
ChiCTR1900021536 |
ChiCTR1900021536 | N/A |
Not yet recruiting |
Nasopharyngeal Cancer |
2025-02-28 |
|||
NCT04845490 |
WUHIPEC02 | P2 |
Not yet recruiting |
Colorectal Cancer |
2023-09-01 |
2022-02-22 |
Primary Endpoints |
|
ChiCTR1800018249 |
ChiCTR1800018249 | N/A |
Recruiting |
Cervical Cancer |
2023-07-01 |
|||
NCT05546255 |
NCC-006461 | P2 |
Unknown status |
Triple Negative Breast Cancer |
2022-12-01 |
2024-09-04 |
Primary Endpoints|Treatments|Trial Status |
|
ChiCTR2000035449 |
ChiCTR2000035449 | N/A |
Not yet recruiting |
Cervical Cancer |
2022-09-30 |
|||
NCT04808466 |
WUHIPEC01 | P2 |
Unknown status |
Gastrointestinal Cancer |
2022-09-01 |
2025-09-03 |
Primary Endpoints|Treatments|Trial Status |
|
ChiCTR2000033338 |
ChiCTR2000033338 | N/A |
Not yet recruiting |
Esophageal Cancer |
2022-07-01 |
|||
ChiCTR2100043027 |
ChiCTR2100043027 | N/A |
Recruiting |
Triple Negative Breast Cancer |
2022-02-02 |
|||
NCT03700359 |
ES-SCLC 001 | P2 |
Unknown status |
Small Cell Lung Cancer |
2020-11-29 |
2024-11-27 |
||
NCT03221608 |
zs6yhmjHIPEC2017 | P3 |
Unknown status |
Colorectal Cancer |
2021-08-01 |
2024-08-03 |
Primary Endpoints|Treatments|Trial Status |
|
NCT03613597 |
L-SCLC-001 | P2 |
Unknown status |
Small Cell Lung Cancer |
2021-01-01 |
2024-11-27 |
Primary Endpoints |
|
ChiCTR1800017254 |
ChiCTR1800017254 | N/A |
Not yet recruiting |
Lung Cancer |
2020-12-31 |
|||
NCT03613753 |
R-SCLC-001 | P2 |
Unknown status |
Small Cell Lung Cancer |
2020-06-01 |
2024-11-27 |
Primary Endpoints|Treatments |
|
ChiCTR-IIR-17011559 |
ChiCTR-IIR-17011559 | N/A |
Recruiting |
Cervical Cancer |
2020-01-01 |
|||
NCT03210389 |
B2016-001-01 | P2 |
Unknown status |
Nasopharyngeal Cancer |
2019-12-01 |
2021-12-03 |
Primary Endpoints|Treatments|Trial Status |
|
NCT03117257 |
NCT03117257 | P2 |
Unknown status |
Squamous Cell Carcinoma|Head and Neck Cancer |
2019-08-19 |
2021-08-24 |
Primary Endpoints|Treatments|Trial Status |